Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three ...

TOKYO-Nintendo's new Switch 2 videogame machine uses a rare-earth magnet to attach its hand-held controllers to the main console, according to a teardown, highlighting the company's vulnerability to ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Obesity medications, once facing shortages, are now widely available. So how do consumers not get scammed into purchasing ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's ...

The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...